Health and Me

Rachel V Thomas

Serum Institute-Led Monoclonal Antibody Clears Dengue Viremia, Fever Within A Day In Phase 2 Trial

Even as <a href="https://www.healthandme.com/health/dengue">dengue</a> continues to wreak havoc globally, with more than 7.37 million cases reported worldwide so far in 2026, an experimental monoclonal antibody (mAb) has shown promise as a potential treatment in a Phase 2 trial.

Led by Pune-based Serum Institute of India, the trial found that <a href="https://www.healthandme.com/health/dengue">Dengue</a>-mAb cleared dengue viremia and fever within 24 hours, offering early evidence of a potential therapeutic effect against the virus.

“This first-in-patient phase 2 randomized clinical trial demonstrated the safety of Dengue-mAb and its action on the clearance of dengue virus and fever,” the researchers, including those from Serum, said. “This is, to our knowledge, the first evidence of a preliminary therapeutic effect in patients with dengue.”

Detailed in JAMA Network Open, the researchers found that the experimental Dengue-mAb was safe and well-tolerated and showed evidence of a therapeutic effect.

Dengue-mAb is a human-engineered, recombinant monoclonal antibody that neutralized all four dengue virus serotypes in animal studies and demonstrated safety in a Phase 1 trial in healthy adults.

Also read: <a href="https://www.healthandme.com/health-news/dengue-chikungunya-zika-carrying-mosquito-breeding-in-uk-are-you-at-risk-article-156042375" data-type="tilCustomLink">Dengue, Chikungunya, Zika-Carrying Mosquito Breeding In UK: Are You At Risk?</a>

The findings were based on a randomized, placebo-controlled trial involving 250 adults with dengue and a history of fever onset within 48 hours. Participants received one of four doses of Dengue-mAb — 3, 5, 7, or 9 milligrams per kilogram (mg/kg) — or a placebo, with 50 participants assigned to each group.

The primary outcomes were reduction in viremia at 24 hours and causally related serious adverse events (SAEs).

The antibody showed rapid activity against dengue virus and fever at all four dose levels tested.

Among participants who had detectable viremia at baseline, those treated with the 5- to 9-mg/kg doses became negative for dengue virus by eight hours, compared with 72 hours with placebo.

At 24 hours, fever clearance ranged from 92.9% to 100% in the Dengue-mAb groups, compared with 58.3% in the placebo group.

Read More: <a href="https://www.healthandme.com/health-wellness/dengue-is-spreading-beyond-monsoons-and-into-new-regions-across-india-says-expert-article-154332385" data-type="tilCustomLink">Dengue Is Spreading Beyond Monsoons And Into New Regions Across India, Says Expert</a>

Dengue affects more than 200 million people each year, mainly in tropical and subtropical regions, and is expanding into new areas amid climate change and rapid urbanisation. The incidence of severe disease is also rising, increasing the need for effective treatments.

The result matters because there is currently no licensed antiviral drug for dengue anywhere in the world. Three vaccines are licensed, but people who develop dengue today generally receive supportive care, including fluids, fever control and monitoring, rather than a treatment that acts directly on the virus.

Dengue-mAb targets the virus, not just the symptoms. The rapid reduction in viremia raises the possibility of a treatment that could change how dengue is managed. However, whether the antibody can prevent severe dengue, hospitalization or deaths is not yet known.

Much of the dengue burden falls on health systems that may struggle to deliver an infused biologic to outpatients within 48 hours of fever onset.

From U-WIN Success To India's Dengue Vaccine, Immunization Expert Shares Roadmap

The finding is still early. Phase 2 trials assess whether a drug produces a measurable effect in a relatively modest number of patients. They are not the studies regulators use to approve a medicine, and this candidate remains years away from becoming widely available.

<h2>Dengue Cases Worldwide And In India</h2>

According to WHO global surveillance data, more than 7.37 million dengue cases have been reported worldwide, including about 2.83 million confirmed cases and more than 5,100 deaths. India has reported more than 33,000 cases and over 40 deaths.

Health Conditions A-Z

health

serum-institute-led-monoclonal-antibody-clears-dengue-viremia-fever-within-a-day-in-phase-2-trial

serum

serum institute of india

dengue cases worldwide

dengue-mab

Monoclonal Antibody

Dengue Monoclonal Antibody

Dengue

cancer

Fibroid Or Rare Cancer? When Common Symptoms Need A Second Opinion

another-child-dies-from-measles-in-us-amid-vaccine-concerns-why-the-virus-is-more-than-a-fever-and-rash

Another Child Dies From Measles In US Amid Vaccine Concerns: Why The Virus Is More Than A Fever And Rash

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Even as dengue continues to wreak havoc globally, with more than 7.37 million cases reported worldwide so far in 2026, an experimental monoclonal antibody (mAb) has shown promise as a potential treatment in a Phase 2 trial.Led by Pune-based Serum Institute of India, the trial found that Dengue-mAb cleared dengue viremia and fever within 24 hours, offering early evidence of a potential therapeutic effect against the virus.“This first-in-patient phase 2 randomized clinical trial demonstrated the safety of Dengue-mAb and its action on the clearance of dengue virus and fever,” the researchers, including those from Serum, said. “This is, to our knowledge, the first evidence of a preliminary therapeutic effect in patients with dengue.”What Did The Trial Find?Detailed in JAMA Network Open, the researchers found that the experimental Dengue-mAb was safe and well-tolerated and showed evidence of a therapeutic effect.Dengue-mAb is a human-engineered, recombinant monoclonal antibody that neutralized all four dengue virus serotypes in animal studies and demonstrated safety in a Phase 1 trial in healthy adults.Also read: Dengue, Chikungunya, Zika-Carrying Mosquito Breeding In UK: Are You At Risk?The findings were based on a randomized, placebo-controlled trial involving 250 adults with dengue and a history of fever onset within 48 hours. Participants received one of four doses of Dengue-mAb — 3, 5, 7, or 9 milligrams per kilogram (mg/kg) — or a placebo, with 50 participants assigned to each group.The primary outcomes were reduction in viremia at 24 hours and causally related serious adverse events (SAEs).The antibody showed rapid activity against dengue virus and fever at all four dose levels tested.Among participants who had detectable viremia at baseline, those treated with the 5- to 9-mg/kg doses became negative for dengue virus by eight hours, compared with 72 hours with placebo.At 24 hours, fever clearance ranged from 92.9% to 100% in the Dengue-mAb groups, compared with 58.3% in the placebo group.Why Does This Matter?Read More: Dengue Is Spreading Beyond Monsoons And Into New Regions Across India, Says Expert Dengue affects more than 200 million people each year, mainly in tropical and subtropical regions, and is expanding into new areas amid climate change and rapid urbanisation. The incidence of severe disease is also rising, increasing the need for effective treatments.The result matters because there is currently no licensed antiviral drug for dengue anywhere in the world. Three vaccines are licensed, but people who develop dengue today generally receive supportive care, including fluids, fever control and monitoring, rather than a treatment that acts directly on the virus.Dengue-mAb targets the virus, not just the symptoms. The rapid reduction in viremia raises the possibility of a treatment that could change how dengue is managed. However, whether the antibody can prevent severe dengue, hospitalization or deaths is not yet known.Much of the dengue burden falls on health systems that may struggle to deliver an infused biologic to outpatients within 48 hours of fever onset.What Happens Next?   The finding is still early. Phase 2 trials assess whether a drug produces a measurable effect in a relatively modest number of patients. They are not the studies regulators use to approve a medicine, and this candidate remains years away from becoming widely available.Dengue Cases Worldwide And In IndiaAccording to WHO global surveillance data, more than 7.37 million dengue cases have been reported worldwide, including about 2.83 million confirmed cases and more than 5,100 deaths. India has reported more than 33,000 cases and over 40 deaths.

serum institute-led monoclonal antibody clears dengue viremia, fever within a day in phase 2 trial

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Serum Institute-Led Monoclonal Antibody Clears Dengue Viremia, Fever Within A Day In Phase 2 Trial

Another Child Dies From Measles In US Amid Vaccine Concerns: Why The Virus Is More Than A Fever And Rash

Dengue, Chikungunya, Zika-Carrying Mosquito Breeding In UK: Are You At Risk?

Pig Kidney Works In Human Body For 271 Days: Why Xenotransplants Could Bridge The Organ Transplant Gap

Health Conditions A-Z

Serum Institute-Led Monoclonal Antibody Clears Dengue Viremia, Fever Within A Day In Phase 2 Trial

Fibroid Or Rare Cancer? When Common Symptoms Need A Second Opinion

Another Child Dies From Measles In US Amid Vaccine Concerns: Why The Virus Is More Than A Fever And Rash